Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May 19;2(4):100964.
doi: 10.1016/j.jscai.2023.100964. eCollection 2023 Jul-Aug.

Evaluation of an Infrapopliteal Drug-Eluting Resorbable Scaffold: Design Methodology for the LIFE-BTK Randomized Controlled Trial

Ramon L Varcoe  1 , Sahil A Parikh  2 , Brian G DeRubertis  3 , Jennifer M Jones-McMeans  4 , Nutte Tarn Teraphongphom  4 , Jin Wang  4 , Raghu Kolluri  5 , Ido Weinberg  6 , Andrew H Holden  7 , Hector M Garcia-Garcia  8 , Steven W C Kum  9 , Marc P Bonaca  10 , Danielle R Bajakian  2 , Lawrence A Garcia  11 , Prakash Krishnan  12 , Ehrin Armstrong  13 , Mehdi H Shishehbor  14 , John Rundback  15 , D Chris Metzger  16
Affiliations

Evaluation of an Infrapopliteal Drug-Eluting Resorbable Scaffold: Design Methodology for the LIFE-BTK Randomized Controlled Trial

Ramon L Varcoe et al. J Soc Cardiovasc Angiogr Interv. .

Abstract

Background: Critical limb-threatening ischemia (CLTI) is a severe condition characterized by rest pain and ischemic tissue loss that affects 5% to 10% of people with peripheral artery disease. In the United States, there are few Food and Drug Administration-approved devices for the primary treatment of arteries below-the-knee (BTK). Unfortunately, all suffer from high restenosis rates due to intimal hyperplasia, elastic recoil, and untreated dissection because of a lack of scaffolding. The Esprit BTK system is a resorbable, drug-eluting scaffold device with the potential to address an unmet need in people suffering from CLTI because of infrapopliteal atherosclerosis. The LIFE-BTK (pivotaL Investigation of saFety and Efficacy of drug-eluting resorbable scaffold treatment-Below The Knee) randomized controlled trial (RCT) is a prospectively designed premarket evaluation of the Esprit BTK drug-eluting resorbable scaffold used in the treatment of those patients.

Methods: The LIFE-BTK trial enrolled 261 subjects with CLTI for the RCT and a further 7 subjects for a pharmacokinetic substudy. The objective of the RCT was to evaluate the safety and efficacy of the Esprit BTK scaffold compared to percutaneous transluminal angioplasty. The primary efficacy end point was a composite of limb salvage and primary patency at 12 months. The primary safety end point is freedom from major adverse limb events and peri-operative death at 6 months and 30 days, respectively. Clinical follow-up care is planned for 5 years.

Conclusions: Novel devices must be tested in RCTs to evaluate their safety and efficacy compared to the standard of care if we are to improve outcomes for this challenging group of patients.

Keywords: absorbable implants; angioplasty; arterial occlusive diseases; ischemia; lower extremity; peripheral arterial disease; polymers; stents.

PubMed Disclaimer

Figures

None
Graphical abstract
Figure 1
Figure 1
The Esprit BTK drug-eluting resorbable scaffold. BTK, below-the-knee.
Central Illustration
Central Illustration
Design of the LIFE-BTK randomized controlled trial.
See this image and copyright information in PMC

References

    1. Mustapha J.A., Brodmann M., Geraghty P.J., et al. Drug-coated vs uncoated percutaneous transluminal angioplasty in infrapopliteal arteries: six-month results of the Lutonix BTK trial. J Invasive Cardiol. 2019;31(8):205–211. - PubMed
    1. Zeller T., Beschorner U., Pilger E., et al. Paclitaxel-Coated Balloon in infrapopliteal arteries: 12-month Results from the BIOLUX P-II Randomized Trial (Biotronik’s-First in Man study of the Passeo-18 LUX drug releasing PTA Balloon Catheter vs. the uncoated Passeo-18 PTA balloon catheter in subjects requiring revascularization of infrapopliteal arteries) JACC Cardiovasc Interv. 2015;8(12):1614–1622. doi: 10.1016/j.jcin.2015.07.011. - DOI - PubMed
    1. Zeller T., Micari A., Scheinert D., et al. The IN.PACT DEEP Clinical Drug-Coated Balloon Trial: 5-Year Outcomes. JACC Cardiovasc Interv. 2020;13(4):431–443. doi: 10.1016/j.jcin.2019.10.059. - DOI - PubMed
    1. Liistro F., Weinberg I., Almonacid Popma A., Shishehbor M.H., Deckers S., Micari A. Paclitaxel-coated balloons versus percutaneous transluminal angioplasty for infrapopliteal chronic total occlusions: the IN.PACT BTK randomised trial. EuroIntervention. 2022;17(17):e1445–e1454. doi: 10.4244/EIJ-D-21-00444. - DOI - PMC - PubMed
    1. Schneider P.A., Laird J.R., Tepe G., et al. Treatment effect of drug-coated balloons is durable to 3 years in the femoropopliteal arteries: long-term results of the IN.PACT SFA Randomized Trial. Circ Cardiovasc Interv. 2018;11(1):e005891. doi: 10.1161/CIRCINTERVENTIONS.117.005891. - DOI - PMC - PubMed

LinkOut - more resources